Results 51 to 60 of about 137,345 (233)

Association of Disease Location and Treatment With Survival in Diffuse Large B-Cell Lymphoma of the Eye and Ocular Adnexal Region. [PDF]

, 2017
Importance: Primary diffuse large B-cell lymphoma (DLBCL) of the ocular region is rare, and the utility of surgery and radiation therapy remains unresolved.
Ahmed, Aseef H H., Foster, C. Stephen, Shields, Carol L.   +2 more
core   +2 more sources

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source

Cerebral type MALT non Hodgkin lymphoma

Revista Cubana de Medicina Militar, 2021
Introduction: Non-Hodgkin's lymphomas generally have their origin in the lymphoid system, there is a great diversity of them, which makes their classification and definitive pathological diagnosis difficult.
Yaimara Zunen Hernández Puentes, Yordan Rodríguez Hernández, Mercedes Rita Salinas Olivares, Wendolin Rodríguez Borges   +3 more
doaj  

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma

Haematologica, 2018
Chemotherapy and hematopoietic stem cell transplantation are effective treatments for most Hodgkin lymphoma patients, however there remains a need for better tumor-specific target therapy in Hodgkin lymphoma patients with refractory or relapsed disease ...
Ziduo Li, Xinsheng Ju, Kenneth Lee, Candice Clarke, Jennifer L. Hsu, Edward Abadir, Christian E. Bryant, Suzanne Pears, Neroli Sunderland, Scott Heffernan, Annemarie Hennessy, Tsun-Ho Lo, Geoffrey A. Pietersz, Fiona Kupresanin, Phillip D. Fromm, Pablo A. Silveira, Con Tsonis, Wendy A. Cooper, Ilona Cunningham, Christina Brown, Georgina J. Clark, Derek N.J. Hart   +21 more
doaj   +1 more source

Malignant lymphomas (ML) and HIV/AIDS Infection in Tanzania. [PDF]

, 2008
\ud HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis.
Amos R Mwakigonja, Ephata E Kaaya, Edward M Mgaya, C Chassagne-Clement, AM Levine, DM Parkin, DM Parkin, A Carbone, VL Ng, E Castanos-Velez, P Biberfeld, JW Said, ST Lim, J Tomas Navarro, E Kaaya, RJ Pelstring, I Joab, OW Mwanda, C Bellan, JN Kitinya, JL Eshleman, PJ Cook, S Lazzi, DM Parkin, AR Mwakigonja, S Franceschi, D Baris, V Beral, ST Lim, SG Fisher, S de Sanjose, EM Mgaya, SP Chai, RL Mbise, Z Aziz, OW Mwanda, LK Tumwine, KC Chang, J Andersson, V Dinand, C Cohen, ST Lim, J Orem, TR Cote, M Llanos, E Castanos-Velez   +45 more
core   +2 more sources

Extranodal non-Hodgkin's lymphoma [PDF]

Cancer, 1980
From 1964 to 1977, 42 patients with Stages I and II non-Hodgkin's lymphoma involving the extranodal sites were seen and treated with curative intent by radiotherapy in the Department of Therapeutic Radiology at Rush-Presbyterian-St. Luke's Medical Center.
S, Reddy, E, Pellettiere, V, Saxena, F R, Hendrickson   +3 more
openaire   +2 more sources

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

Advanced Science, EarlyView.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang, Pan Lai, Mingjia Li, Yujie Wen, Mengzhou Cao, Yu Xiao, Zhuojing Chen, Jingru Sun, Yang Wang   +8 more
wiley   +1 more source

Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies

Haematologica, 2018
Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk.
Mara M. Epstein, Bernard Rosner, Elizabeth C. Breen, Julie L. Batista, Edward L. Giovannucci, Larry Magpantay, Jon C. Aster, Scott J. Rodig, Kimberly A. Bertrand, Francine Laden, Otoniel Martínez-Maza, Brenda M. Birmann   +11 more
doaj   +1 more source